LOGIN  |  REGISTER
Recursion

Clover Health to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

February 26, 2024 | Last Trade: US$2.89 0.33 12.89

FRANKLIN, Tenn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will report fourth quarter and full year 2023 financial results after market close on Tuesday, March 12, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on March 12, 2024 to discuss the Company’s business and financial results.

Fourth Quarter and Full Year 2023 Conference Call and Webcast Details:

  • What: Clover Health Fourth Quarter and Full Year 2023 Earnings Conference Call
  • When: Tuesday, March 12, 2024, at 5:00 p.m. Eastern Time
  • Dial In: To access the call via telephone please dial 800-579-2543 (for U.S. callers) or 785-424-1789 (for callers outside the U.S.) and enter the conference ID: CLOVQ423
  • Webcast: A live and archived webcast of the conference call will be accessible from the Investor Relations section of the Company’s website at https://investors.cloverhealth.com/ for 12 months

About Clover Health

Clover Health (Nasdaq: CLOV) is a physician enablement company committed to bringing access to great healthcare to everyone on Medicare. This includes a health equity-based focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease.

Press Contact:
Andrew Still-Baxter
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations Contact:
Ryan Schmidt
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page